Loïck Galland

548 total citations
25 papers, 298 citations indexed

About

Loïck Galland is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Loïck Galland has authored 25 papers receiving a total of 298 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 4 papers in Molecular Biology. Recurrent topics in Loïck Galland's work include Cancer Immunotherapy and Biomarkers (8 papers), Lung Cancer Treatments and Mutations (8 papers) and Colorectal Cancer Treatments and Studies (6 papers). Loïck Galland is often cited by papers focused on Cancer Immunotherapy and Biomarkers (8 papers), Lung Cancer Treatments and Mutations (8 papers) and Colorectal Cancer Treatments and Studies (6 papers). Loïck Galland collaborates with scholars based in France, United States and Luxembourg. Loïck Galland's co-authors include Sylvain Ladoire, François Ghiringhelli, Emeric Limagne, Caroline Truntzer, Courèche Kaderbhaï, Julie Malo, Antoine Desîlets, Scott M. Lippman, Andréanne Gagné and Bertrand Routy and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Loïck Galland

24 papers receiving 291 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Loïck Galland France 11 181 80 61 48 42 25 298
Theresa Czech Austria 6 70 0.4× 84 1.1× 65 1.1× 25 0.5× 38 0.9× 16 273
Matthew C. Dallos United States 11 288 1.6× 170 2.1× 163 2.7× 205 4.3× 62 1.5× 32 473
Yizhuo Gao China 7 130 0.7× 152 1.9× 78 1.3× 49 1.0× 43 1.0× 17 354
Massimiliano Grassi Italy 9 120 0.7× 101 1.3× 81 1.3× 62 1.3× 66 1.6× 23 290
Anni Innamaa United Kingdom 5 209 1.2× 31 0.4× 89 1.5× 41 0.9× 79 1.9× 13 343
Huiyu Lu China 11 144 0.8× 82 1.0× 120 2.0× 23 0.5× 76 1.8× 29 303
Laurence Servais Belgium 7 54 0.3× 33 0.4× 91 1.5× 33 0.7× 77 1.8× 10 256
Bernard S. Buetow United States 8 114 0.6× 20 0.3× 76 1.2× 51 1.1× 20 0.5× 13 228
Xueguo Sun China 10 65 0.4× 46 0.6× 138 2.3× 14 0.3× 123 2.9× 25 292
Janine Lombard Australia 11 204 1.1× 64 0.8× 88 1.4× 42 0.9× 78 1.9× 38 395

Countries citing papers authored by Loïck Galland

Since Specialization
Citations

This map shows the geographic impact of Loïck Galland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Loïck Galland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Loïck Galland more than expected).

Fields of papers citing papers by Loïck Galland

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Loïck Galland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Loïck Galland. The network helps show where Loïck Galland may publish in the future.

Co-authorship network of co-authors of Loïck Galland

This figure shows the co-authorship network connecting the top 25 collaborators of Loïck Galland. A scholar is included among the top collaborators of Loïck Galland based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Loïck Galland. Loïck Galland is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Greillier, Laurent, Florian Guisier, Catherine Daniel, et al.. (2025). Real-world efficacy and safety of amivantamab in EGFR exon-20-mutant non-small cell lung cancer in a French early-access program: Amexon 20 GFPC study. Lung Cancer. 209. 108766–108766.
2.
Ladoire, Sylvain, Loïck Galland, Isabelle Desmoulins, et al.. (2025). Prevalence, clinicopathologic features and long-term overall survival of early breast cancer patients eligible for adjuvant abemaciclib and/or ribociclib. npj Breast Cancer. 11(1). 10–10. 1 indexed citations
3.
Galland, Loïck, Valentin Dérangère, David Rageot, et al.. (2025). Co-targeting TGF-β and PD-L1 sensitizes triple-negative breast cancer to experimental immunogenic cisplatin-eribulin chemotherapy doublet. Journal of Clinical Investigation. 135(13). 3 indexed citations
4.
Bergstrom, Erik N., Ammal Abbasi, Marcos Díaz‐Gay, et al.. (2024). Deep Learning Artificial Intelligence Predicts Homologous Recombination Deficiency and Platinum Response From Histologic Slides. Journal of Clinical Oncology. 42(30). 3550–3560. 17 indexed citations
5.
6.
Jacob, Pierre, Isabelle Desmoulins, Sylvie Zanetta, et al.. (2024). Carboplatin and Etoposide for the Treatment of Metastatic Prostate Cancer with or without Neuroendocrine Features: A French Single-Center Experience. Cancers. 16(2). 280–280. 1 indexed citations
7.
Bergstrom, Erik N., Ammal Abbasi, Marcos Díaz‐Gay, et al.. (2024). Abstract LB391: Deep learning AI predicts HRD and platinum response from histologic slides. Cancer Research. 84(7_Supplement). LB391–LB391. 1 indexed citations
8.
Galland, Loïck, et al.. (2023). Simultaneous isolation of CD45 tumor-infiltrating lymphocytes, tumor cells, and associated fibroblasts from murine breast tumor model by MACS. STAR Protocols. 4(1). 101951–101951. 1 indexed citations
9.
Galland, Loïck, Isabelle Desmoulins, Didier Mayeur, et al.. (2023). Clinical Utility of Genomic Tests Evaluating Homologous Recombination Repair Deficiency (HRD) for Treatment Decisions in Early and Metastatic Breast Cancer. Cancers. 15(4). 1299–1299. 10 indexed citations
10.
11.
Galland, Loïck, Elise Ballot, Romain Boidot, et al.. (2022). Efficacy of platinum-based chemotherapy in metastatic breast cancer and HRD biomarkers: utility of exome sequencing. npj Breast Cancer. 8(1). 28–28. 14 indexed citations
12.
Ballot, Elise, Loïck Galland, Romain Boidot, et al.. (2022). Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancers. Breast Cancer Research. 24(1). 80–80. 7 indexed citations
13.
Galland, Loïck, et al.. (2022). Impact of Glucocorticoid Use in Oncology in the Immunotherapy Era. Cells. 11(5). 770–770. 43 indexed citations
14.
15.
Deschênes‐Simard, Xavier, Corentin Richard, Loïck Galland, et al.. (2021). Venous thrombotic events in patients treated with immune checkpoint inhibitors for non-small cell lung cancer: A retrospective multicentric cohort study. Thrombosis Research. 205. 29–39. 44 indexed citations
16.
Galland, Loïck, Laure Favier, Aurélie Lagrange, et al.. (2021). Splenic Volume as a Surrogate Marker of Immune Checkpoint Inhibitor Efficacy in Metastatic Non Small Cell Lung Cancer. Cancers. 13(12). 3020–3020. 13 indexed citations
17.
Descourt, R., M. Pérol, David Planchard, et al.. (2020). 1392P Brigatinib in patients with ALK-positive advanced non-small cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study). Annals of Oncology. 31. S884–S884. 1 indexed citations
18.
19.
Descourt, R., M. Pérol, David Planchard, et al.. (2019). Brigatinib in pretreated patients with ALK-positive advanced NSCLC.. Journal of Clinical Oncology. 37(15_suppl). 9045–9045. 3 indexed citations
20.
Galland, Loïck. (1987). Biochemical abnormalities in patients with multiple chemical sensitivities.. PubMed. 2(4). 713–20. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Theresa Czech Breakdown of academic impact, for papers by Matthew C. Dallos Breakdown of academic impact, for papers by Yizhuo Gao Breakdown of academic impact, for papers by Massimiliano Grassi Breakdown of academic impact, for papers by Anni Innamaa Breakdown of academic impact, for papers by Huiyu Lu Breakdown of academic impact, for papers by Laurence Servais Breakdown of academic impact, for papers by Bernard S. Buetow Breakdown of academic impact, for papers by Xueguo Sun Breakdown of academic impact, for papers by Janine Lombard
Rankless by CCL
2026